Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine
合作旨在加快個性化療法的開發,並通過使用精準醫療改變患者護理
TAMPA, Fla. & LOS ANGELES--(BUSINESS WIRE)--May 14, 2024-- Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced today a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives. This collaboration combines Moffitt's cutting-edge clinical capabilities with Fulgent's groundbreaking nanotherapeutics and genomics platforms in an effort to accelerate the development of personalized cancer therapies. Under the agreement, Moffitt will provide Fulgent with priority access to its clinical expertise and resources, with the aim of expediting the advancement of Fulgent's clinical pipeline. This priority access at Moffitt includes prioritized clinical trial activation, enhanced patient screening, and data sharing designed to get investigational therapies to patients in need more quickly and efficiently.
佛羅里達州坦帕和洛杉磯--(美國商業資訊)--2024年5月14日--世界知名的癌症治療和研究中心莫菲特癌症中心和富爾金特基因公司(納斯達克股票代碼:FLGT)的子公司、一家專門從事創新癌症療法的領先納米生物技術公司今天宣佈了一項戰略合作伙伴關係,旨在通過臨床開發和臨床前共同開發計劃推進癌症治療。此次合作將Moffitt的尖端臨床能力與Fulgent開創性的納米療法和基因組學平台相結合,旨在加速個性化癌症療法的開發。根據該協議,莫菲特將向富爾金特提供優先獲得其臨床專業知識和資源的機會,目的是加快富爾金特臨床管道的發展。Moffitt的這種優先訪問權限包括優先激活臨床試驗、加強患者篩查以及數據共享,旨在更快、更高效地爲有需要的患者提供研究性療法。
Fulgent Pharma, a leader in nanoencapsulation technology, has transformed paclitaxel, a chemotherapy drug known for its poor solubility, into a soluble counterpart suitable for intravenous injection called FID-007. In Phase 1 clinical studies conducted with FID-007 to date, substantial tumor reduction across various cancer types, including breast, head and neck, lung, bile duct, and pancreatic cancers, has been observed.
納米膠囊化技術的領導者Fulgent Pharma已將一種以溶解度差而聞名的化療藥物紫杉醇轉化爲一種名爲 FID-007 的適合靜脈注射的可溶性對應物。在迄今爲止使用 FID-007 進行的 1 期臨床研究中,已觀察到各種癌症(包括乳腺癌、頭頸癌、肺癌、膽管癌和胰腺癌)的腫瘤顯著減少。
Additionally, the partnership will focus on co-developing next-generation personalized treatment options for cancer. Moffitt will leverage its broad scientific and immunology expertise, access to tissue samples and nonclinical research resources, while Fulgent will contribute its novel and proprietary nano-particle-based drug development platform along with its broad spectrum genetic and genomic testing capabilities.
此外,該合作伙伴關係將側重於共同開發下一代癌症個性化治療方案。Moffitt將利用其廣泛的科學和免疫學專業知識、組織樣本和非臨床研究資源的渠道,而Fulgent將貢獻其基於納米顆粒的新型專有藥物開發平台及其廣譜遺傳和基因組測試能力。
"Pooling our unique strengths, Moffitt and Fulgent will strive to create new precision oncology therapies customized to meet the specific needs of each patient, thereby improving future outcomes," said Fulgent Pharma President and CSO Ray Yin, Ph.D.
Fulgent Pharma總裁兼首席安全官Ray Yin博士表示:“彙集我們的獨特優勢,Moffitt和Fulgent將努力開發新的精準腫瘤療法,以滿足每位患者的特定需求,從而改善未來的療效。”
"This partnership aligns with Moffitt's mission to contribute to the prevention and cure of cancer. We are looking forward to working with Fulgent to accelerate the translation of scientific discoveries into lifesaving treatments for our patients," said Moffitt President and CEO Patrick Hwu, M.D.
“這種夥伴關係符合莫菲特的使命,即爲癌症的預防和治療做出貢獻。我們期待與富爾金特合作,加快將科學發現轉化爲患者挽救生命的治療方法。” 莫菲特總裁兼首席執行官帕特里克·胡醫學博士說。
"We are excited to collaborate with Moffitt Cancer Center, a global cancer research and treatment leader," said Ming Hsieh, CEO of Fulgent Genetics. "By combining Moffitt's clinical and research expertise with Fulgent's innovative nanotherapeutic platform and growing patent portfolio, we believe we can make significant strides in advancing personalized cancer treatment options."
Fulgent Genetics首席執行官謝明說:“我們很高興與全球癌症研究和治療領導者莫菲特癌症中心合作。”“通過將Moffitt的臨床和研究專業知識與Fulgent的創新納米治療平台和不斷增長的專利組合相結合,我們相信我們可以在推進個性化癌症治療選擇方面取得重大進展。”
About Moffitt Cancer Center
關於莫菲特癌症中心
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Moffitt 致力於一項拯救生命的使命:爲癌症的預防和治療做出貢獻。位於坦帕的設施是僅有的57個設施之一 國家癌症研究所指定的綜合癌症中心,這一榮譽是對莫菲特卓越的科學成就、多學科研究以及強有力的培訓和教育的認可。莫菲特的專業護理人員獲得了美國護士資格認證中心的認可,這是其最高榮譽。欲了解更多信息,請致電 1-888-MOFFITT (1-888-663-3488),請訪問 moffitt.org,然後繼續保持勢頭 Facebook, 推特, Instagram 和 優酷。
About Fulgent Pharma
關於富爾金特製藥
Fulgent Pharma began as part of Fulgent LLC in Temple City, California, established in June 2011. As the company progressed into the sphere of precision medicine, it also started delving into clinical genetic and genomic testing - a natural complement. In 2016, Fulgent LLC split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives. In 2022, Fulgent Pharma was acquired by Fulgent Genetics to synergistically advance personalized cancer genomics and precision oncology therapeutics. Today, Fulgent Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers. Its partners in this endeavor include the University of Southern California, Moffitt Cancer Center, and ANP Technologies. For more information visit FulgentGenetics.com.
Fulgent Pharma最初是位於加利福尼亞州天普市的富爾金特有限責任公司的一部分,該公司成立於2011年6月。隨着公司進入精準醫療領域,它還開始研究臨床遺傳和基因組測試,這是一種天然的補充。2016年,Fulgent LLC拆分爲兩個獨立的實體- 富爾金特製藥 和 Fulgent 遺傳學 -以便更好地實現其獨立目標。2022年,Fulgent Pharma被Fulgent Genetics收購,以協同推進個性化癌症基因組學和精準腫瘤療法。如今,Fulgent Pharma完全專注於完善用於治療各種癌症的候選藥物。其在這項工作中的合作伙伴包括南加州大學、莫菲特癌症中心和ANP Technologies。欲了解更多信息,請訪問 FulgentGenetics.com。
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: future performance; Fulgent Pharma's research and development efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials, the expected timing of enrollment and regulatory filings for these trials and the availability of data or results of these trials, including any implication that interim or preliminary data will be representative of final results, the intended benefits of the collaboration, including whether the collaboration expedites development of any of Fulgent Pharma's product candidates. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or Fulgent Pharma's future performance, and they are based on management's current assumptions, expectations, and beliefs concerning future developments and their potential effect on Fulgent Pharma's business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the success of Fulgent Pharma's development efforts, including its ability to progress its candidates through clinical trials on the timelines expected; its compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and its ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.
本新聞稿包含1995年《私人證券訴訟改革法》所指的前瞻性陳述。本新聞稿中的前瞻性陳述示例包括以下方面的陳述:未來表現;Fulgent Pharma的研發工作,包括對早期臨床試驗結果具有代表性或與後期臨床試驗一致的任何影響、這些試驗的預期註冊和監管機構申報時間以及這些試驗的數據或結果的可用性,包括任何暗示中期或初步數據將代表最終結果的暗示、預期的益處合作,包括合作是否加快了Fulgent Pharma任何候選產品的開發。前瞻性陳述是歷史事實以外的陳述,與未來事件或情況或富爾金特製藥的未來業績有關,它們基於管理層當前對未來發展及其對富爾金特製藥業務的潛在影響的假設、預期和信念。這些前瞻性陳述存在許多風險和不確定性,這可能導致本新聞稿中描述的前瞻性事件和情況不發生,實際結果與前瞻性陳述中描述或暗示的結果存在重大和不利的差異。除其他外,這些風險和不確定性包括:Fulgent Pharma開發工作的成功,包括其按預期時間表通過臨床試驗推進候選藥物的能力;其遵守適用於其業務和行業的各種不斷變化的複雜法律法規的情況;以及保護其專有技術和知識產權的能力。由於這些風險和不確定性,不應依賴前瞻性陳述或將其視爲對未來事件的預測。
The forward-looking statements made in this press release speak only as of the date of this press release, and Fulgent Pharma and Fulgent Genetics assume no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.
本新聞稿中的前瞻性陳述僅代表截至本新聞稿發佈之日,除非法律另有規定,否則Fulgent Pharma和Fulgent Genetics沒有義務公開更新任何此類前瞻性陳述以反映實際業績或預期變化。
Fulgent Genetics, Inc.'s reports filed with the U.S. Securities and Exchange Commission, or the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 28, 2024, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on the Fulgent Genetic's website upon their filing with the SEC. These reports contain more information about Fulgent Genetics and Fulgent Pharma, their business and the risks affecting their business.
Fulgent Genetics, Inc.向美國證券交易委員會(SEC)提交的報告,包括其於2024年2月28日向美國證券交易委員會提交的截至2023年12月31日財政年度的10-K表年度報告,以及其不時提交的其他報告,包括隨後提交的年度、季度和當前報告,在向美國證券交易委員會提交後,將在Fulgent Genetic的網站上公佈。這些報告包含有關Fulgent Genetics和Fulgent Pharma、他們的業務以及影響其業務的風險的更多信息。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514935253/en/
Patty Kim
Moffitt Cancer Center
813-745-7322
Patty.Kim@Moffitt.org
Patty Kim
莫菲特癌症中心
813-745-7322
Patty.Kim@Moffitt.org
Melanie Solomon
The Blueshirt Group
melanie@blueshirtgroup.com
梅蘭妮·所羅門
Blueshirt 集團
melanie@blueshirtgroup.com
Source: Fulgent Pharma
來源:富爾金特製藥
譯文內容由第三人軟體翻譯。